173 related articles for article (PubMed ID: 19295274)
1. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274
[TBL] [Abstract][Full Text] [Related]
2. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].
Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M
Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672
[TBL] [Abstract][Full Text] [Related]
3. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
4. [A case of locally advanced breast cancer successfully treated by pre-operative systemic therapy using paclitaxel and trastuzumab].
Suda T; Ishiguro K; Nishimura M
Gan To Kagaku Ryoho; 2008 Jun; 35(6):979-81. PubMed ID: 18633228
[TBL] [Abstract][Full Text] [Related]
5. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
Sikov WM; Dizon DS; Strenger R; Legare RD; Theall KP; Graves TA; Gass JS; Kennedy TA; Fenton MA
J Clin Oncol; 2009 Oct; 27(28):4693-700. PubMed ID: 19720916
[TBL] [Abstract][Full Text] [Related]
6. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
[TBL] [Abstract][Full Text] [Related]
8. [A case of advanced accessory breast cancer effectively treated with trastuzumab and paclitaxel].
Suzuki S; Ohchi T; Doi K; Ogata K; Maeda T; Kudo K; Ishihara A
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1615-7. PubMed ID: 18799924
[TBL] [Abstract][Full Text] [Related]
9. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
[TBL] [Abstract][Full Text] [Related]
10. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
11. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
[TBL] [Abstract][Full Text] [Related]
13. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
15. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.
Sonke GS; Mandjes IA; Holtkamp MJ; Schot M; van Werkhoven E; Wesseling J; Vrancken Peeters MJ; Rodenhuis S; Linn SC
Breast J; 2013; 19(4):419-26. PubMed ID: 23682812
[TBL] [Abstract][Full Text] [Related]
17. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer.
Shimizu T; Hirano A; Kamimura M; Ogura K; Kim N; Watanabe O; Kinoshita J; Kimura K; Ogawa K; Fujibayashi M
Anticancer Res; 2010 Nov; 30(11):4665-71. PubMed ID: 21115921
[TBL] [Abstract][Full Text] [Related]
20. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]